TransMedics Group, Inc. (TMDX) stock
TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3030% below fair value
$93.91+1.70 (+1.84%)
Close on Nov 17, 2026Market cap $3.26BP/E 24.4Yield 0.00%
TransMedics r&d expenses
Research and development expenses are spending on new products and technology.
TransMedics's R&D Expenses for the twelve months ending Jun 30, 2026 was $92.47M, up 44.9% year over year. For fiscal 2025 it was $69.06M, up 23.4% from the year before. The highest annual figure on record is $69.06M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.06M | +23.4% |
| FY2024 | Dec 31, 2024 | $55.97M | +55.2% |
| FY2023 | Dec 31, 2023 | $36.06M | +34.5% |
| FY2022 | Dec 31, 2022 | $26.81M | +20.2% |
| FY2021 | Dec 31, 2021 | $22.30M | +18.4% |
| FY2020 | Dec 31, 2020 | $18.83M | -5.2% |
| FY2019 | Dec 28, 2019 | $19.87M | +45.5% |
| FY2018 | Dec 29, 2018 | $13.66M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $31.63M | +98.5% |
| Q1 FY2026 | Mar 31, 2026 | $24.88M | +45.0% |
| Q4 FY2025 | Dec 31, 2025 | $20.70M | +25.7% |
| Q3 FY2025 | Sep 30, 2025 | $15.26M | +7.0% |
| Q2 FY2025 | Jun 30, 2025 | $15.93M | +15.0% |
| Q1 FY2025 | Mar 31, 2025 | $17.16M | +50.8% |
| Q4 FY2024 | Dec 31, 2024 | $16.46M | +53.0% |
| Q3 FY2024 | Sep 30, 2024 | $14.27M | +28.2% |
| Q2 FY2024 | Jun 30, 2024 | $13.86M | +67.1% |
| Q1 FY2024 | Mar 31, 2024 | $11.38M | +93.8% |
| Q4 FY2023 | Dec 31, 2023 | $10.76M | +87.0% |
| Q3 FY2023 | Sep 30, 2023 | $11.13M | +63.5% |
| Q2 FY2023 | Jun 30, 2023 | $8.29M | +23.5% |
| Q1 FY2023 | Mar 31, 2023 | $5.87M | -22.1% |
| Q4 FY2022 | Dec 31, 2022 | $5.76M | -8.8% |
| Q3 FY2022 | Sep 30, 2022 | $6.81M | +31.9% |
| Q2 FY2022 | Jun 30, 2022 | $6.71M | +6.7% |
| Q1 FY2022 | Mar 31, 2022 | $7.53M | +66.2% |
| Q4 FY2021 | Dec 31, 2021 | $6.31M | +38.8% |
| Q3 FY2021 | Sep 30, 2021 | $5.16M | +24.3% |
| Q2 FY2021 | Jun 30, 2021 | $6.30M | +61.3% |
| Q1 FY2021 | Mar 31, 2021 | $4.53M | -27.2% |
| Q4 FY2020 | Dec 31, 2020 | $4.55M | -27.4% |
| Q3 FY2020 | Sep 30, 2020 | $4.16M | -15.9% |
| Q2 FY2020 | Jun 30, 2020 | $3.90M | -18.5% |
| Q1 FY2020 | Mar 31, 2020 | $6.23M | +60.4% |
| Q4 FY2019 | Dec 28, 2019 | $6.26M | +79.6% |
| Q3 FY2019 | Sep 28, 2019 | $4.94M | +50.9% |
| Q2 FY2019 | Jun 29, 2019 | $4.79M | +39.4% |
| Q1 FY2019 | Mar 30, 2019 | $3.88M | +12.0% |
| Q4 FY2018 | Dec 29, 2018 | $3.49M | – |
| Q3 FY2018 | Sep 29, 2018 | $3.27M | – |
| Q2 FY2018 | Jun 30, 2018 | $3.43M | – |
| Q1 FY2018 | Mar 31, 2018 | $3.47M | – |
See a number that looks wrong?